News Search Results
Nov 05, 2025, 07:00 ET InMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.
More news about: InMode Ltd.
Nov 04, 2025, 19:00 ET Multiple Research Results from Innovent's General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting
that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced that pre-clinical study results of IBI3011 (IL-1RAP monoclonal antibody) and IBI3034 (TACI/BCMA chimeric
More news about: Innovent Biologics
Nov 04, 2025, 10:16 ET ZEISS Opens New Connecticut Quality Excellence Center to Strengthen Northeast Manufacturing
quality assurance, microscopy solutions for life sciences and materials research, and medical technology solutions for diagnostics and therapy in ophthalmology and microsurgery for its customers. ZEISS also stands for the world's leading lithography optics, which is used by the chip industry to manufacture
More news about: Carl Zeiss Industrial Quality Solutions, LLC
Nov 03, 2025, 15:00 ET Dr. Max D. Schlesinger Joins OCLI Vision in Mineola and Rockville Centre
of Retina Specialists and the Association for Research in Vision and Ophthalmology. He is board certified by the American Board of Ophthalmology and is an active member of the American Academy of Ophthalmology and the American Society of Retina Specialists. "I'm
More news about: OCLI Vision
Nov 03, 2025, 10:15 ET Dr. Andrea N. Nortey Joins OCLI Vision in Mineola and Oceanside
Humanism Honor Society for her exceptional professionalism, integrity, and dedication to compassionate care. She completed her ophthalmology residency at the Albert Einstein College of Medicine/Montefiore Medical Center in the Bronx, NY, where she trained extensively in both medical and
More news about: OCLI Vision
Nov 03, 2025, 10:00 ET Avisi Technologies Announces Positive Twelve-Month Clinical Data of VisiPlate® Aqueous Shunt at AAO 2025
technologies, presented positive twelve-month clinical data on VisiPlate® Aqueous Shunt from the VITA Trial during the 2025 American Academy of Ophthalmology (AAO) annual meeting. The study was presented by Dr. Jonathan Myers, Chief of Glaucoma Service at Wills Eye Hospital, Thomas Jefferson University.
More news about: Avisi Technologies
Nov 03, 2025, 08:05 ET InMode Appoints Michael Dennison as President of North America
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
More news about: InMode Ltd.
Nov 03, 2025, 00:00 ET Happiest Health Launches Happiest Pearls Dental Clinic in Indiranagar
Healthcare Services (HCS) business specializes in multiple disciplines. We currently offer Dental and Orthopedic services. We will soon offer ENT, Ophthalmology, Pediatrics, Obesity & Weight management, Urology and other disciplines. The Wellness business too has a range of clinics
More news about: Happiest Health Systems Pvt LTD
Nov 01, 2025, 03:00 ET Two Billion Live with Vision Impairment -- Can AI Help Prevent Sight Loss?
vision impairment—many cases preventable. Against that backdrop, Prof. Keane details how demand for eye care now outpaces capacity: in the UK, ophthalmology is the busiest medical specialty, accounting for nearly 10% of all NHS appointments—about 10 million annually—up by more than a third in five years.
More news about: Planet Classroom Network
Oct 31, 2025, 08:00 ET Mallinckrodt to Present Data on Terlipressin at the 2025 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
diseases in areas including endocrinology, gastroenterology, hepatology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology, and urology. Our Par Health business includes generic drugs, sterile injectables, and active pharmaceutical ingredients.
More news about: Mallinckrodt plc
Oct 30, 2025, 20:37 ET Revolutionary Cataract Surgery Technology Transforms Eye Care with Precision and Enhanced Patient Outcomes
reduce surgical complications and improve visual outcomes across a broad patient base. Barnet Dulaney Perkins is committed to advancing the field of ophthalmology and providing state-of-the-art care to those in need of vision restoration. For more information or
More news about: Barnet Dulaney Perkins Eye Center
Oct 30, 2025, 10:47 ET Rovia Clinical Research Announces Partnership with the Hattiesburg Clinic to Launch New Research Site in Hattiesburg, Mississippi
Across its 15 sites and 80+ investigators, Rovia's core research focus includes endocrinology, obesity, cardiology, gastroenterology, neurology, ophthalmology and infectious disease. Rovia has a proven history of enrolling patients with best-in class retention, rapid study-start up and high-quality data.
More news about: Rovia Clinical Research
Oct 30, 2025, 08:30 ET InMode to Participate in Upcoming Investor Conferences
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
More news about: InMode Ltd.
Oct 30, 2025, 08:00 ET Mallinckrodt to Present Data on Terlipressin in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at Kidney Week 2025
diseases in areas including endocrinology, gastroenterology, hepatology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology, and urology. Our Par Health business includes generic drugs, sterile injectables, and active pharmaceutical ingredients.
More news about: Mallinckrodt plc
Oct 30, 2025, 03:28 ET U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)
monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific
More news about: Celltrion
Oct 30, 2025, 01:21 ET Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Solutions
Oct 30, 2025, 01:15 ET Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Solutions
Oct 29, 2025, 19:00 ET ZEISS and LG Chem join forces to strengthen the photopolymer supply chain for advanced optics
assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture
More news about: ZEISS Microoptics
Oct 29, 2025, 15:22 ET Surgical Sutures Market to Reach USD 7,923.8 million by 2032, Growing At An 6.92% CAGR - Credence Research
market. In October 2024, Corza Medical unveiled its Onatec Ophthalmic Microsurgical Sutures at the American Academy of Ophthalmology Conference, marking a key expansion in ophthalmic solutions. In September 2024, Meril Life Sciences launched the New
More news about: Credence Research Inc.
Oct 29, 2025, 14:37 ET University of Miami Health System's Bascom Palmer Eye InstituteOpening in Abu Dhabi
Bascom Palmer Eye Institute Abu Dhabi to be one of the finest medical institutions devoted to ophthalmology, not only in the country and the Gulf Cooperation Council but also in the larger Middle East and North Africa region. Given the breadth and depth
More news about: Bascom Palmer Eye Institute
Oct 28, 2025, 10:15 ET As Part of November's Diabetes-related Eye Disease Month, Prevent Blindness Launches New Resources to Educate Public on the Effects Diabetes has on Vision
will host a special roundtable discussion about diabetes and eye health. Guests include Rajeev S. Ramchandran, MD, MBA, associate professor of ophthalmology at University of Rochester
More news about: Prevent Blindness
Oct 28, 2025, 09:00 ET Luminopia Collaborates with Crunchyroll to Continue Building Its Extensive Content Library for Pediatric Lazy Eye Patients
results were published in Ophthalmology, leading to the initial FDA approval for patients aged 4 to 7 years. Based on the robust real-world evidence collected through the PUPiL Registry,
More news about: Luminopia
Oct 28, 2025, 08:12 ET AMSURG Increases South Carolina Presence With Addition of Conway Surgery Center
health systems, the organization delivers high-quality patient care across a diverse spectrum of medical specialties, including gastroenterology, ophthalmology and orthopedics. Guided by its core values — Care Deeply, Champion Excellence, Cultivate Integrity and Celebrate Teamwork — AMSURG is committed
More news about: AMSURG Corporation
Oct 24, 2025, 08:30 ET Lilly to Acquire Adverum Biotechnologies
Adverum, regarding Adverum's product candidates and ongoing clinical and preclinical development, and regarding Lilly's development of programs for ophthalmology and advancement of gene therapies. All statements other than statements of historical fact are statements that could be deemed forward-looking statements.
More news about: Eli Lilly and Company
Oct 23, 2025, 08:30 ET Improve Clinical Trial Delivery by Leveraging AI Forecasting Tools, Upcoming Webinar Hosted by Xtalks
the PPD Clinical Research Business of Thermo Fisher Scientific, Tim Mudric, Vice President Global Therapeutic Head, Neuroscience and Ophthalmology; and Dave Hiltbrand, Associate Director of Data Science, for the live webinar on Monday, November 10, 2025, with
More news about: Xtalks